INVA — Innoviva, Inc. stock price, charts and financials

Latest market price

20.68

+0.17+0.83%

Overview Short InterestFilings

INVAQT52Innoviva, Inc.·NASDAQ

Overview Short InterestFilings

20.68+0.83%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.64%$16.68 ZBIO-1.48%$31.95 GHRS-2.44%$29.53 TSHA-2.90%$6.37 STOK-1.47%$32.23 ABCL+34.78%$9.34 VRDN-2.25%$23.06

Snapshot

Index	-	P/E	4.21	EPS (ttm)	4.87	Insider Own	-	Shs Outstand	73.81M	Perf Week	-2.19%

Market Cap	1.51B	Forward P/E	8.75	EPS next Y	2.35	Insider Trans	0.00%	Shs Float	69.20M	Perf Month	-7.61%

Enterprise Value	1.21B	PEG	0.01	EPS next Q	-	Inst Own	-	Short Float	10.14%	Perf Quarter	-10.04%

Income	359.08M	P/S	3.41	EPS this Y	-44.69%	Inst Trans	-	Short Ratio	8.53	Perf Half Y	-4.91%

Sales	443.43M	P/B	1.22	EPS next Y	-29.45%	ROA	20.98%	Short Interest	7.02M	Perf YTD	2.60%

Book/sh	-	P/C	6.64	EPS next 5Y	-10.95%	ROE	30.03%	52W High	25.36 -18.45%	Perf Year	12.38%

Cash/sh	-	P/FCF	6.79	EPS past 3/5Y	11.67% 10.31%	ROIC	8.36%	52W Low	16.66 24.15%	Perf 3Y	55.61%

Dividend Est.	-	EV/EBITDA	1.47	Sales past 3/5Y	8.69% 4.75%	Gross Margin	73.09%	Volatility	3.55% 2.40%	Perf 5Y	44.64%

Dividend TTM	-	EV/Sales	2.74	EPS Y/Y TTM	1569.44%	Oper. Margin	36.66%	ATR (14)	0.63	Perf 10Y	75.30%

Dividend Ex-Date	Sep 08, 2015	Quick Ratio	15.18	Sales Y/Y TTM	18.11%	Profit Margin	80.56%	RSI (14)	38.36	Recom	2.60

Dividend Gr. 3/5Y	-	Current Ratio	16.01	EPS Q/Q	76.00%	SMA20	-4.02%	Beta	0.33	Target Price	38.00

Payout	0.00%	Debt/Eq	0.22	Sales Q/Q	10.11%	SMA50	-6.85%	Rel Volume	1.34	Prev Close	20.51

Employees	159	LT Debt/Eq	0.23	Earnings	Nov 04	SMA200	-5.10%	Avg Volume	852.51K	Price	20.68

IPO Date	Oct 05, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.82% -3.52%	Net Debt/EBITDA	-0.37	Volume	1,143,234	Change	0.83%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-07-26	Reiterated	Cantor Fitzgerald	Overweight	$36 → $34
May-07-26	Reiterated	BTIG	Buy	$35 → $42
Feb-26-26	Reiterated	Cantor Fitzgerald	Overweight	$32
Feb-17-26	Initiated	BTIG	Buy	$35
Dec-16-25	Reiterated	HC Wainwright & Co.	Buy	$46
Sep-30-25	Initiated	Goldman Sachs	Sell	$17
Aug-11-25	Initiated	Oppenheimer		$35
Mar-07-25	Initiated	Scotiabank	Outperform	$55
Aug-08-22	Reiterated	Morgan Stanley	Underweight	$12 → $13
Jul-15-22	Reiterated	Morgan Stanley	Underweight	$12

Latest News

Aug-06-26

Aug-06-2607:31AM

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimisticseekingalpha.com

Aug-05-26

Aug-05-2609:36PM

Innoviva (INVA) Q2 Earnings and Revenues Top Estimateszacks.com

04:43PM

Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M EstimateBenzinga

04:05PM

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progressbusinesswire.com

Aug-03-26

Aug-03-2610:05AM

Supernus Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com

Jul-29-26

Jul-29-2604:17AM

Dimensional Fund Advisors LP Acquires 76,026 Shares of Innoviva, Inc. $INVAdefenseworld.net

Jul-28-26

Jul-28-2611:21AM

Innoviva (INVA): Affordable Growth Stock at a Reasonable ValuationChartMill

Jul-07-26

Jul-07-2609:40AM

Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong FundamentalsChartMill

Jun-27-26

Jun-27-2612:00PM

INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical BreakoutChartMill

Jun-18-26

Jun-18-2612:00PM

Nortiva Bio Launches to Develop Long-Acting Oral MedicinesYahoo

11:40AM

Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05ChartMill

08:08AM

Nortiva Bio Launches Clinical-Stage Biopharmaceutical Company To Develop Long-Acting Oral MedicinesBenzinga

Jun-16-26

Jun-16-2612:00PM

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International MarketsYahoo

08:05AM

Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga

Company

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	444	425	359	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	119	118	37	—	—	—	—	—	—
Gross Profit	325	308	322	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	126	113	116	—	—	—	—	—	—
Research and Development	29	31	14	—	—	—	—	—	—
Other Operating Expense	7	0	25	—	—	—	—	—	—
Operating Income	163	164	167	—	—	—	—	—	—
Interest Expense	17	17	22	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	275	180	-107	—	—	—	—	—	—
Net Income Before Taxes	420	327	37	—	—	—	—	—	—
Income Taxes	62	56	14	—	—	—	—	—	—
Consolidated Net Income	358	271	23	—	—	—	—	—	—
Net Income From Continuing Operations	358	271	23	—	—	—	—	—	—
Net Income	358	271	23	—	—	—	—	—	—
EPS (Recurring)	4.87	4.02	0.37	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	4.87	4.02	0.37	—	—	—	—	—	—
EPS (Diluted)	4.10	3.30	0.36	—	—	—	—	—	—
EBITDA	822	384	85	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	5.04	6.06	48.19	—	—	—	—	—	—
Price To Sales Ratio	3.40	3.15	3.04	—	—	—	—	—	—
Gross Margin	73.20	72.47	89.69	—	—	—	—	—	—
Operating Margin	36.71	38.59	46.52	—	—	—	—	—	—
Net Margin	80.63	63.76	6.41	—	—	—	—	—	—
Shares Outstanding	73	67	63	—	—	—	—	—	—
Market Capitalization	1,510	1,339	1,093	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DENNER ALEXANDER J	10% Owner	Mar 06 '25	Sale	17.52	1,196,746	20,964,237	5,658,705	Mar 06
DENNER ALEXANDER J	10% Owner	Mar 05 '25	Sale	17.63	270,374	4,766,126	6,855,451	Mar 06
DENNER ALEXANDER J	10% Owner	Mar 04 '25	Sale	17.63	151,175	2,665,079	7,125,825	Mar 06
Zhen Marianne	Chief Accounting Officer	Nov 15 '23	Sale	13.99	10,994	153,810	40,158	Nov 17
DENNER ALEXANDER J	10% Owner	Jun 15 '23	Buy	13.13	62,000	814,196	7,277,000	Jun 20
DENNER ALEXANDER J	10% Owner	Jun 06 '23	Buy	13.05	8,000	104,384	7,215,000	Jun 07
DENNER ALEXANDER J	10% Owner	Jun 05 '23	Buy	13.04	7,000	91,297	7,207,000	Jun 07
DENNER ALEXANDER J	10% Owner	May 30 '23	Buy	13.01	120,000	1,560,648	7,200,000	May 30
DENNER ALEXANDER J	10% Owner	May 26 '23	Buy	13.12	30,000	393,729	7,080,000	May 30
DENNER ALEXANDER J	10% Owner	May 25 '23	Buy	13.09	50,000	654,330	7,050,000	May 30
DENNER ALEXANDER J	10% Owner	May 19 '23	Buy	13.48	36,000	485,147	7,000,000	May 19
DENNER ALEXANDER J	10% Owner	May 18 '23	Buy	13.05	10,000	130,538	6,964,000	May 19
DENNER ALEXANDER J	10% Owner	May 17 '23	Buy	13.07	50,000	653,690	6,954,000	May 19
DENNER ALEXANDER J	10% Owner	May 11 '23	Buy	12.34	290,000	3,577,411	6,904,000	May 15
Raifeld Pavel	Chief Executive Officer	Mar 10 '23	Buy	10.87	3,000	32,603	9,799	Mar 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.